Investigator meeting · Dr. Daniel Tanaka

22 Jun 2026 · Virtual · Dr. Daniel Tanaka, Policlinico Gemelli · MSL James Whitfield · Vantrexa

ReviewedManualENG-0015—

Capture insight from this engagement

Location: Policlinico Gemelli
Therapeutic area: Oncology
Country: Italy
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Comparator checkpoint monotherapy
Infusion-reaction management

Scientific content used

PD-L1 testing pathway infographic
VTX core scientific deck v3.2

Questions raised

No questions recorded.

Notes

Investigator meeting with thoracic medical oncologist at Policlinico Gemelli. Discussed comparator checkpoint monotherapy, infusion-reaction management.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 2
Strategic relevance: 4
Depth of exchange: 3
Actionability: 2

Data lineage

Source system: Manual
Sync: Entered manually in Hub
System of record: Hub
Record id: ENG-0015

Audit history (0)

All create, update and approval events for this record

No audit events in sample data